Web of Science: 1 cites, Scopus: 1 cites, Google Scholar: cites,
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
Salvador-Martín, Sara (Hospital General Universitario Gregorio Marañón)
Rubbini, Gianluca (Hospital General Universitario Gregorio Marañón)
Vellosillo, Perceval (Hospital General Universitario Gregorio Marañón)
Zapata-Cobo, Paula (Hospital General Universitario Gregorio Marañón)
Velasco, Marta (Hospital Infantil Universitario Niño Jesús (Madrid))
Palomino, Laura M (Hospital Infantil Universitario Niño Jesús (Madrid))
Clemente, Susana (Hospital Universitari Vall d'Hebron)
Segarra, Oscar (Hospital Universitari Vall d'Hebron)
Moreno-Álvarez, Ana (Complejo Hospitalario Universitario de A Coruña)
Fernández-Lorenzo, Ana (Complejo Hospitalario Universitario de A Coruña)
Pérez-Moneo, Begoña (Hospital Universitario Infanta Leonor)
Montraveta, Montserrat (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sánchez, Cesar (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Tolín, Mar (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Loverdos, Inés (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Fobelo, María José (Universidad de Sevilla)
Navas-López, Víctor Manuel (Hospital Regional Universitario de Málaga)
Magallares, Lorena (Hospital Universitario La Paz (Madrid))
García-Romero, Ruth (Hospital Universitario Miguel Servet (Saragossa))
Torres-Peral, Ricardo (Complejo Asistencial Universitario de Salamanca)
Rodríguez, Alejandro (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Bossacoma, Ferrán (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Merino-Bohórquez, V. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Salcedo, Enrique (Hospital 12 de Octubre (Madrid))
Álvarez, Rebeca (Genomics Unit (Madrid))
Dopazo, Ana (Genomics Unit (Madrid))
Sanjurjo-Sáez, María (Hospital General Universitario Gregorio Marañón)
López-Fernández, Luis A. (Hospital General Universitario Gregorio Marañón)

Data: 2024
Resum: Background/aims: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes that could serve as predictors of early response to anti-TNF therapies in pediatric IBD patients prior to the initiation of treatment. Methods: We conducted a prospective, longitudinal, and multicenter study, enrolling 24 pediatric IBD patients aged less than 18 years who were initiating treatment with either infliximab or adalimumab. RNA-seq from blood samples was analyzed using the DESeq2 library by comparing responders and non-responders to anti-TNF drugs. Results: Bioinformatic analyses unveiled 102 differentially expressed genes, with 99 genes exhibiting higher expression in responders compared to non-responders prior to the initiation of anti-TNF therapy. Functional enrichment analyses highlighted defense response to Gram-negative bacteria (FDR = 2. 3 ×10-7) as the most significant biological processes, and hemoglobin binding (FDR = 0. 002), as the most significant molecular function. Gene Set Enrichment Analysis (GSEA) revealed notable enrichment in transcriptional misregulation in cancer (FDR = 0. 016). Notably, 13 genes (CEACAM8, CEACAM6, CILP2, COL17A1, OLFM4, INHBA, LCN2, LTF, MMP8, DEFA4, PRTN3, AZU1, and ELANE) were selected for validation, and a consistent trend of increased expression in responders prior to drug administration was observed for most of these genes, with findings for 4 of them being statistically significant (CEACAM8, LCN2, LTF2, and PRTN3). Conclusions: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.
Ajuts: Instituto de Salud Carlos III PI19/00792
Instituto de Salud Carlos III PI22/00584
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: RNA-seq ; Pharmacogenomics ; Inflammatory bowel disease ; Anti-TNF drugs ; Pediatrics ; RNA-seq Pharmacogenomics Inflammatory bowel disease Anti-TNF drugs Pediatrics
Publicat a: Biomedicine & pharmacotherapy, Vol. 173 (april 2024) , p. 116299, ISSN 1950-6007

DOI: 10.1016/j.biopha.2024.116299


13 p, 4.7 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2024-10-10, darrera modificació el 2024-11-09



   Favorit i Compartir